
(12) UK Patent Application (19) GB (11) 2 105 192 A

- (21) Application No 8224638
(22) Date of filing 27 Aug 1982
(30) Priority data
(31) 297076
(32) 27 Aug 1981
(33) United States of America
(US)
(43) Application published
23 Mar 1983
(51) INT CL³
A61K 31/395 31/19 31/38
31/135 31/335
(52) Domestic classification
A5B 180 190 20X 20Y 293
29X 29Y 410 41Y 420 421
424 426 42Y 430 431 432
43Y 463 46Y 471 47Y 480
482 483 486 48Y 493 49Y
502 503 506 50Y 541 54Y
550 551 552 553 554 55Y
566 56Y 575 576 577 57Y
586 615 616 617 61Y 644
646 647 64Y 650 657 65Y
660 664 66Y 670 671 67Y J
(56) Documents cited
None
(58) Field of search
A5B
(71) Applicants
Shaun R Coughlin,
130 Bowdoin Street,
Apt 1006,
Boston,
Massachusetts 02108,
United States of America.
(72) Inventors
Shaun R. Coughlin
(74) Agents
J.A. Kemp and Co.,
14 South Square,
Gray's Inn,
London WC1R 5EU.

(54) Composition for use in treating
atherosclerosis

(57) A pharmaceutical composition
comprises at least two drugs wherein
each drug is from a different group of
drugs selected from (i) tryptophan hyd-
roxylase inhibitors, (ii) peripheral decar-
boxylase inhibitors, (iii) serotonin up-
take blockers, (iv) serotonin storage
blockers and (v) serotonin receptor
blockers. In use the composition in-
hibits the biological activity of serotonin
within the blood vessels, thereby in-
hibiting the proliferation of smooth
muscle cells, which has been found to
cause or contribute to an arteriosclero-
tic condition. Many drugs are specified.

GB 2 105 192 A

SPECIFICATION**Composition for use in treating atherosclerosis**

- 5 The most widely accepted model (Ross, et al, New England Journal of Medicine, 295, 369-377 and 420-425, 1976; and Friedman, et al, Prog. Hemostasis and Thrombosis, 4 249-278, 1978) for the process of atherogenesis involves hemodynamic, immunologic or metabolic injury to the endothelial lining of a blood vessel, which causes the underlying smooth muscle layer to be exposed to blood elements. In this model, circulating platelets adhere to the damaged blood vessel wall, releasing their granule contents. This event 5 appears to be vital in initiating the next step in the atherogenic process, which is the migration of smooth 10 muscle cells from the medial layer of the blood vessel, where they normally reside, into the arterial intima (the inner layer of the vessel) and their subsequent proliferation. These intimal smooth muscle cells synthesize extracellular matrix material and imbibe lipid to produce the foam cells seen in atherosclerotic 15 blood vessels. It is this overgrowth of smooth muscle cells, together with increased matrix material and lipid, which narrows the blood vessel lumen, compromising blood flow and causing an increased tendency for 20 blood to clot and obstruct the affected vessel. Strategies for the prophylaxis and treatment of atherogenesis in the past have been directed at reducing risk factors for the disease, such as lowering blood pressure in hypertensive subjects, treating diabetics and reducing elevated cholesterol levels in hypercholesterolemic 25 subjects.
- 20 Since local accumulation of smooth muscle cells within the arterial intima is central to the development of atherosclerotic lesions, one very important strategy for the prophylaxis and treatment of arteriosclerosis is to suppress smooth muscle cell proliferation. Blood platelets are the likely bearers of the messenger for smooth muscle proliferation. After the endothelial lining of the blood vessel has been damaged, platelets carpet the denuded area, liberating their granule contents into the circulation and into the vessel wall.
- 25 Serotonin, calcium, adenosine triphosphate and adenosine diphosphate are liberated from platelet dense bodies. Platelet alpha granules release beta-thromboglobulin, platelet factor IV, platelet fibrinogen and platelet-derived growth factor. The functions of these various compounds are not well understood, although it appears that they are important to hemostasis and/or repair of the damaged vessel. Platelet-derived growth factor has been shown by others to be a mitogen for smooth muscle cells. Due to the nature of 30 platelet-derived growth factor, it has not been possible to assess the role played by this molecule in stimulation of smooth muscle proliferation *in vivo*. Prior to the present invention, a role for platelet serotonin, in stimulating smooth muscle cell proliferation, had also not been known or demonstrated. It has now been found that serotonin is a potent promoter of smooth muscle proliferation in cell culture and is important in mediating smooth muscle proliferation after vascular injury *in vivo*. It is the object of this 35 invention to control this biological signal for smooth muscle proliferation in the blood vessel intima so as to control the condition of arteriosclerosis. It is especially applicable where hypertension, existing arteriosclerosis, vascular surgery associated with accelerated smooth muscle proliferation and risk of vessel occlusion, or diabetes significantly increase the risk of arteriosclerosis development.
- Accordingly, the present invention provides a composition for use in inhibiting the smooth muscle cell 40 proliferation activity of serotonin within blood vessels; in limiting and reversing the progression of arteriosclerosis resulting from smooth muscle cell proliferation; and in preventing the development of the disease where there is a high risk of developing this condition.
- The pharmaceutical composition of the invention comprises a mixture of at least two drugs wherein each drug is from a different group of drugs selected from (i) tryptophan hydroxylase inhibitors, (ii) peripheral 45 decarboxylase inhibitors, (iii) serotonin uptake blockers, (iv) serotonin storage blockers and (v) serotonin receptor blockers.
- The pharmaceutical composition of the invention is useful in the treatment of arteriosclerosis and in limiting the progression of arteriosclerosis resulting from vascular smooth muscle cell proliferation. More particularly, smooth muscle cell proliferation in the injured blood vessel of a mammal is inhibited when the 50 pharmaceutical composition is administered to the mammal in an effective smooth muscle proliferation inhibiting amount.
- In order to interfere with the signal for smooth muscle cell proliferation, the composition of the invention is employed to reduce the biological activity of platelet-released serotonin within the blood vessels. Use of the composition can be supplemented by the use of a diet lean or poor in tryptophan, which decreases the 55 amount of serotonin precursor available for conversion to serotonin. The administration orally, parenterally or otherwise of the composition of the invention interferes with, blocks, inhibits or decreases any serotonin precursor or serotonin itself in the blood. The composition and optional diet may be used in combination with other known drugs or treatments for arteriosclerotic conditions, for example antiplatelet drugs, antihypertensive agents, lipid-lowering techniques or other medical treatments or drugs, including drugs 60 which inhibit the synthesis of serotonin or the availability of its precursor tryptophan.
- The activity of serotonin in the blood may be reduced by an artificial diet, as indicated above, markedly low or lacking in the essential amino acid tryptophan, which is needed for the synthesis of serotonin. This can be accomplished through the use of a corn-based diet, which is tryptophan-poor, or an artificial amino-acid mixture from which tryptophan is eliminated. Because of undesirable side effects resulting from the absence 65 of an essential amino acid, the use of anti-serotonin agents is preferred.

A first group of drugs which may be used to inhibit smooth muscle cell proliferation are those which interfere with the conversion of tryptophan to serotonin, specifically tryptophan hydroxylase inhibitors (for example, p-chloro-phenylalanine) and aromatic amino acid decarboxylase inhibitors (for example, carbidopa). Serotonin is synthesized in the gut enterochromaffin cells and in the central nervous system and is taken up by the blood platelet via a specific uptake system and stored in platelet organelles known as dense bodies. The first and most specific enzyme in this pathway is tryptophan hydroxylase. This enzyme is the rate-limiting compound in serotonin synthesis, and blocking the activity of this enzyme will decrease the amount of serotonin produced. Tryptophan hydroxylase inhibitors, such as p-chloro-phenylalanine, thus reduce the quantity of serotonin available for action at the blood vessel wall and are useful for the treatment of atherosclerosis. The second enzyme involved in the synthesis of serotonin is 5-hydroxytryptophan decarboxylase. Agents that selectively block the activity of this enzyme also decrease serotonin production and, thus, are useful in the treatment of atherosclerosis. Carbidopa is an example of a prototype drug of this type as indicated above.

A second group of anti-serotonin agents which may be used are serotonin uptake blockers, for example, fluoxetine or amitriptyline, which prevent serotonin uptake by platelets. Platelet serotonin after synthesis in the gut enterochromaffin cells, is released into the blood, where it is rapidly transported into the blood platelet via a specific transport system or degraded by the ubiquitous enzyme, monoamine oxidase. Inhibition of the platelet's serotonin transport system therefore leads to functional depletion of platelet serotonin stores; and hence, less serotonin is available to act at the blood vessel wall. Existing serotonin uptake blockers, such as amitriptyline (Elavil) or fluoxetine, are therefore useful agents in the prophylaxis and treatment of arteriosclerosis.

Agents that interfere with serotonin storage may also be employed to deplete platelet serotonin stores in the dense bodies. Tetraabenazine and drugs of the Rauwolfa alkaloid class, such as reserpine (serpasil, Raurine and Reserpoid), interfere with serotonin storage, effectively depleting the platelet of its serotonin content. It has been found that reserpine, in combination with the serotonin receptor blocker methiothepin, can reduce markedly smooth muscle proliferation after experimental vascular injury.

Serotonin receptor blockers, such as methiothepin, metergoline, methysergide, cyproheptadine and especially pizotyline (4-[1-methyl-4-piperidylidene]-9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thiophene) are the preferred group employed to interfere specifically with and inhibit the proliferating action of serotonin on smooth muscle cells. Serotonin receptor blockers provide the most effective and specific approach to limiting the ability of platelet-released serotonin to stimulate smooth muscle cell proliferation. Released serotonin acts at specific receptors on the smooth muscle cell surface and this interaction can be blocked by serotonin antagonists, such as those mentioned above and also butyrophenones such as spiroperidol and haloperidol; and others such as cinanserin and mianserin. Pizotyline and methiothepin have been found to be remarkably effective in preventing smooth muscle cell proliferation after experimental vascular injury.

In addition to the serotonin antagonist categories above, agents which act as inhibitors of platelet activation will decrease platelet aggregation and platelet adhesion to injured blood vessel walls, thereby also decreasing serotonin release. Examples of agents that act in this fashion are: 1) agents that act to raise platelet cyclic AMP, either by increasing its synthesis, for example, prostacyclin or prostaglandin E₁, and their analogues or by decreasing its degradation, for example, the phosphodiesterase inhibitors, sulfinpyrazone or dipyridamole; 2) agents that decrease platelet thromboxane A₂ synthesis, for example, cyclooxygenase inhibitors, such as aspirin or indomethacin, or thromboxane synthetase inhibitors, such as imidazoles; and 3) agents that block calcium influx into platelets, that is, calcium channel blockers, such as verapamil. The use of agents in this group, for the purpose of inhibiting platelet/vessel wall interaction and thereby decreasing smooth muscle proliferation, is already known in the art. However, these agents are useful in combination with compounds specifically directed at blocking the action of serotonin, for example, pizotyline and methiothepin.

The antiserotonin strategy involving use of the composition of the invention may be employed either alone or in combination with another antiserotonin intervention approach as described or in combination with anti-platelet drugs or other appropriate medical therapies, such as antihypertensive agents and lipid-lowering techniques. By administering the pharmaceutical composition of the invention, comprising a combination of serotonin antagonist agents, each of which acts with relative specificity at a different site in the pathway from tryptophan intake to serotonin's action at the smooth muscle receptor, the possibility of achieving maximum inhibition of serotonin's action is increased. In addition, the relative specificity of the intervention is increased, and the dosages of the individual agents can be minimized to avoid undesirable side effects, which are well known in the art. The preferred strategy is the use of a composition comprising a serotonin receptor blocker in combination with one or more antiserotonin agents selected from serotonin synthesis inhibitors, serotonin storage blockers, serotonin uptake blockers or blood platelet inhibitors, specially serotonin storage blockers and inhibitors of platelet function.

While the individual pharmaceutical agents of the compositions of the invention are known in the art, they have not been utilized in combination for the prophylaxis or treatment of arteriosclerosis by inhibiting smooth muscle cell proliferation. Other serotonin receptor blockers, which may be used in this invention include ketanserin, desipramine, imipramine, chlorimipramine, protriptyline, dibenzepine, amitriptyline, doxepin, prothiadene, pirandamine, spirobenzofuran, ciclazindol, nefopam, deximafen, daledalin, amedalin,

- quipazine, trazodone, zimelidine, tofenacine, fenetazole and fenflurame. Additional compounds which have serotonin antagonist activity and can be used are 11-amino-1,5-methano-1,2,5,6-tetrahydrobenzocine; 1-methylamino-4-phenyl-1,2,3,4-tetrahydronaphthylene; 6-cyano-1,3-dihydro-3-dimethylaminopropyl-3-(p-fluorophenyl)-isobenzofuran; 4-benzyl-1-(2-benzofurancarbonyl)piperide, 1,4-ethano-4-phenyl-5 cyclohexylamine, α -(p-chlorophenyl)-2-methylamino-methylbenzyl alcohol; α -(2-methylaminoethyl)-2-methoxy or 4-trifluoromethylphenylbenzyl ether or p-anisyl-(1-methyl-4-phenyl-3-pipecolinyl)-ether.
- Inhibitors of serotonin synthesis, uptake or storage would preferably be administered orally in doses sufficient to cause a fall in platelet serotonin levels. The actual and effective dose of drug used for these purposes is determined by monitoring platelet serotonin content essentially as described by Rao, et al (An Improved Method for the Extraction of Endogenous Platelet Serotonin, J. Lab. Clin. Med., 87, No. 1, 129-137, 1976). Inhibitors of platelet function have been used in humans; and the actual dose of inhibitor to be employed may be determined by monitoring inhibition of *ex vivo* platelet aggregation essentially as described by R. Friedman and E. Burns ("Role of Platelets in the proliferative response of the Injured Artery"; Prog. Hemostasis and Thrombosis; 4 249-278, 1978). Serotonin receptor blockers have also been used in humans, and the actual dose of the blocker to be used can also be determined by monitoring of *ex vivo* platelet aggregation in response to serotonin and determining the amount of serotonin receptor blocker necessary to block this effect. Additional methods for monitoring serotonin, serotonin uptake or serotonin uptake inhibition in blood platelet are described by Wielosz, et al (Naunyn-Schneideberg's Arch. Pharmacol. 296, 59-65, 1976); O. Lingjaerde (Adv. Biosci, 31, 161-167, 1981); Tuomisto (J. Pharm. Pharmac., 26, 92-100; 20 1974); Richter, et al (J. Pharm. Pharmac., 26 763-770, 1974); and Tuomisto, et al (Clin. Pharmacol. Ther., 63, No. 11, 1714-1718, 1974).
- In order to demonstrate the efficiency of serotonin antagonists as inhibitors of smooth muscle proliferation after vascular injury (and thus as effective agents in ameliorating the development of atheromas), the following experimental strategy, among others, has been employed.
- The use of serotonin antagonists in preventing or impeding arteriosclerotic lesion is indicated in vivo essentially in accordance with the de-endothelialization procedure of Tiell, et al (Influence of the Pituitary on Arterial Intima Proliferation in the Rat, Circulation Research, Vol. 42, No. 5, 644-149, May 1978). Male Sprague-Dawley rats weighing 300-360 grams are fed a constant formula rodent lab chow and water ad libitum for two weeks prior to the start of the test. For two days before de-endothelialization and for the following 14 days until sacrifice, the animals receive either a placebo or 1 to 200 milligrams per kilogram per day of test compound. On the day of de-endothelialization, the drug is administered intravenously at one-tenth the oral dosage. De-endothelialization is carried out in the aortas of the anesthetized animals by balloon catheterization. The animals are weighed daily from the time of dosing and their behaviour is recorded 3 to 4 hours following administration of the test compound. Fourteen days after catheterization, whole body perfusion fixation is carried out at 37°C. with 3% buffered glutaraldehyde in 0.15 M sodium cacodylate at pH 7.4 under 90-100 millimeters hydrostatic pressure. The aorta is removed, cut into 10 equal segments, and following two additional hours in the buffered glutaraldehyde, is treated with 1% osmium tetroxide, dehydrated, infiltrated with Squer's resin and cured. The segments are stained with Stevenal's blue and basic fuchsin, and the lesion areas is determined with a Zeiss standard microscope and Videoplan computerized image analyzer (see Example 5 below).
- For the treatment and prophylaxis of atherosclerosis, the compositions of the invention, optionally containing anti-platelet agents, may be administered orally or parenterally as such or mixed with conventional pharmaceutical carriers. They may be administered orally in such forms as tablets, dispersible powders, granules, capsules, syrups and elixirs, and parenterally as solutions, e.g. a sterile injectable aqueous solution. The compositions for oral use may contain one or more conventional adjuvants, such as sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide an elegant and palatable preparation. Tablets may contain the active ingredients mixed with conventional pharmaceutically acceptable excipients, e.g. inert diluents, such as calcium carbonate, sodium carbonate, lactose and talc, granulating and disintegrating agents, e.g. starch and alginic acid, and binding agents, e.g. magnesium stearate, stearic acid and talc. The tablets may be coated by known techniques to delay disintegration and absorption in the gastro-intestinal tract and thereby provide a sustained action over a longer period. Similarly, suspensions, syrups and elixirs may contain the active ingredients mixed with any of the conventional excipients utilized in the preparation of such compositions, e.g. suspending agents such as methylcellulose, tragacanth and sodium alginate; wetting agents such as lecithin, polyoxyethylene stearate and polyoxyethylene sorbitan monoleate; and preservatives such as ethyl *p*-hydroxybenzoate. Capsules may contain the active ingredients alone or mixed with an inert solid diluent, e.g. calcium carbonate, calcium phosphate and kaolin. The injectable compositions are formulated as known in the art. These pharmaceutical preparations may contain up to 90% of the active ingredients in combination with the carrier or adjuvant. The effective amount of serotonin antagonist employed in the treatment of arteriosclerosis will vary widely depending on the particular compound employed, the mode of administration and the severity of the condition being treated. The optimum dose is readily determined by the methods indicated above. The dose should be sufficient to reduce smooth muscle cell proliferation by at least 20% and preferably from 40% to 95%. In general satisfactory results in the treatment of arteriosclerosis are obtained when a serotonin receptor blocker is administered at a daily dosage of from about 2 milligram to about 200 milligrams, preferably 15 to 50 milligrams, per kilogram of animal body weight, preferably given orally once a day, or in

sustained release form. For most large mammals, the total daily dosage is from about 1 milligram to about 1000 milligrams, preferably 5 to 200 milligrams. Unit dosage forms suitable for internal use comprise from about 1 milligram to about 500 milligrams, in intimate mixture with a solid or liquid, pharmaceutically acceptable carrier.

5 The invention will be described further by reference to the following examples. 5

Example 1

Smooth muscle cells are grown from explants of bovine aortic media as described by Coughlin, et al (Platelet-Dependent Stimulation of Prostacyclin Synthesis by Platelet Derived Growth Factor, *Nature*, 288, 10 pp. 600-602, 1980). Cells are seeded at 10^5 cells per 35 mm tissue culture well in Dulbecco's Modified Eagle Medium containing 10% calf serum and allowed to grow for 24 hours. The serum-containing medium is then removed and the cells are allowed to become quiescent in Medium 199 for 24 hours. The quiescent cultures are then incubated for 72 hours in Medium 199, with or without the mitogen to be tested. After the 72-hour incubation period, the cells are harvested for cell-number determination by Coulter Counter. 15 Table I shows that more smooth muscle cells are present in cultures that are treated with 10^5 moles of serotonin. This effect is observed in both the presence and absence of 2% human platelet-poor plasma which has been reported to allow for better expression of mitogenic activity. Platelet-derived growth factor (PDGF), a known mitogen for smooth muscle cells, is also seen to be active in this system. 15

		TABLE I Cell Number/Plate		
		$(\times 10^{-5})$		
20	Treatment	No Plasma	Plasma	20
25	Control	6.60 ± 0.20	5.75 ± 0.14	25
30	Serotonin $(10^{-5}M)$	8.34 ± 0.43	12.19 ± 0.13	30
35	PDGF (8 ng/ml)	9.65 ± 0.29	14.24 ± 0.04	35
40	Serotonin + PDGF (8 ng/ml)	10.51 ± 0.27	14.36 ± 0.14	40
Mean \pm SEM (n=6)				

Example 2

Smooth muscle cells are seeded and made quiescent as described in Example 1. Cultures are then treated with serotonin, PDGF or cyproheptadine, a serotonin receptor blocker. The cultures are then incubated for 96 hours in Medium 199 containing 2.5% platelet-poor plasma and the treatment to be tested. The results are set forth in Table II. 45

This example shows that serotonin increases the number of smooth muscle cells present at the end of the test period, and that this increase is attenuated by the serotonin receptor blocker, cyproheptadine. Serotonin causes increases in smooth muscle cell number above and beyond those caused by low concentrations of PDGF, and these serotonin-induced increases are again attenuated by cyproheptadine. Fetal calf serum, which is known to promote smooth muscle proliferation maximally is employed as a positive control. 50 Similar results are obtained using the serotonin receptor blockers, metergoline and methiothepin. Other serotonin receptor blockers, such as pizotyline, methysergide, spiroperidol mianserin, yield similar results.

TABLE II

	Treatment	Cell Number/Plate ($\times 10^{-5}$)	% Maximum*	
5	Control	5.0 ± 0.19	0	5
	Serotonin 10 ⁻⁵ M	7.68 ± 0.12	33	
10	Serotonin + Cyproheptadine 10 ⁻⁶ M	5.87 ± 0.15	10	10
	PDGF 0.5 ng/ml	8.11 ± 0.23	39	
15	PDGF 0.5 ng/ml + Serotonin	10.40 ± 0.06	68	15
	PDGF 0.5 ng/ml ± Serotonin + Cyproheptadine	9.57 ± 0.14	58	
20	PDGF 4.0 ng/ml	10.66 ± 0.16	72	20
	PDGF 4.0 ng/ml + Serotonin	12.01 ± 0.09	89	
25	PDGF 4.0 ng/ml + Serotonin + Cyproheptadine	11.11 ± 0.07	77	25
	1% Fetal Calf Serum	8.24 ± 0.20	40	
30	5% Fetal Calf Serum	11.16 ± 0.11	78	30
	10% Fetal Calf Serum	12.86 ± 0.11	100	
35				
40				40

BASMC P₃ Mean ± SEM (n=6) 2.5% 96-hour incubation * % Maximum = (Value for Treatment group - value for Control group ÷ (Value for 10% Fetal Calf Serum - value for Control group) × 100.

45 **Example 3**

In this experiment, stimulation of ³H-thymidine incorporation is used as an index of the ability of a compound to promote smooth muscle cell proliferation. Smooth muscle cells are seeded in 96 well Linbro racks (5 mm diameter/well) and allowed to grow for 72 hours. Cells are next allowed to become quiescent in Medium 199 for 24 hours. To start an incubation, cells are incubated with 200 µl of Medium 199 containing 50 2.5% platelet-poor plasma, ³H-thymidine (5uCi/ml) and treatment or control. After approximately 36 hours, the cells are washed with saline, fixed with 10% TCA, washed with water, lysed with 1% SDS, and the lysate counted for ³H. This procedure allows the investigator to assess the amount of ³H-thymidine taken up by smooth muscle cells and incorporated into DNA. This process occurs to the extent that cells are proliferating and, hence, is used to test the ability of substances to stimulate cell proliferation.

45

50

The data of Table III obtained in this test show that serotonin stimulates smooth muscle cell proliferation, as indicated by increased ^3H -thymidine incorporation, in a dose-dependent manner. Furthermore, the results show that the serotonin receptor blocker, cyproheptadine (cypro, 10^{-7}M) attenuates this response to serotonin. Platelet-derived growth factor (1 ng/ml) known to stimulate smooth muscle cell proliferation also 5 is shown to increase thymidine incorporation.

5

TABLE III

	Treatment	CPM/Well ($\times 10^{-3}$)	% Increase	
10	Control	90.0 \pm 7.2	0	10
15	1% FCS	290.3 \pm 25.9	222	15
15	Serotonin 10^{-7}M	139.8 \pm 11.9	55	15
20	Serotonin 10^{-6}M	306.4 \pm 3.1	240	20
20	Serotonin 10^{-7}M + Cypro	85.9 \pm 6.5	-4	20
25	Serotonin 10^{-6}M + Cypro	237.4 \pm 23.8	163	25
25	Platelet-derived growth factor	454.7 \pm 28.3	405	25
30	Mean \pm SEM (n=4)	FCS = Fetal Calf Serum		30

Similar results are obtained when the cyproheptadine is replaced by other serotonin receptor blockers such as pizotyline.

35 Example 4

35

This example demonstrates that interventions which reduce the activity of serotonin within blood vessels in the whole animal dramatically reduce the proliferation of smooth muscle cells after vascular injury. Rat aortas are denuded of endothelium by passing a catheter with an inflated balloon at its tip down the length of the blood vessel. In animal models, this type of vascular injury has been shown by Goldberg, et al (Vascular 40 Smooth Muscle Cell Kinetics: A New Assay For Studying Patterns of Cellular Proliferation *In Vivo*, *Science*, 205, 920-922, 1979), to stimulate formation of vascular lesions resembling those of human atherosclerosis 48 hours after injury. The rats are injected intravenously with ^3H -thymidine, which is incorporated into the DNA of proliferating smooth muscle cells. After one hour, the specific activity of aortic smooth muscle cell DNA is determined and used as an index of smooth muscle cell proliferation in the injured vessel wall. The data 45 obtained are set forth in Table IV.

40

Pretreatment of animals with the serotonin receptor blocker, methiothepin (10 mg/kg i.p., b.i.d.) leads to a marked inhibition of injury-induced, smooth muscle cell proliferation. Other serotonin receptor blockers, such as pizotyline, cyproheptadine, methysergide, metergoline or mianserin give similar results. By adding reserpine to the regimen, a drug that depletes platelet serotonin stores (pretreatment for one week at 0.5 50 mg/kg i.p. q.d.), further reductions in smooth muscle cell proliferation are achieved. These results show that drugs which act to reduce the activity of serotonin within blood vessels prevent smooth muscle cell proliferation in the whole animal after vascular injury, and that such interventions prevent or reverse proliferative vascular lesions, which occur in atherosclerosis.

45

50

TABLE IV

Specific activity of aortic smooth muscle cell DNA after experimental vascular injury: Effects of Antiserotonin treatments

		Specific Activity (CPM/ugDNA)		
5	Control	91.6 ± 13.7	(8)	5
10	Methiothepin-treated	18.1 ± 5.3	(6)	10
15	Methiothepin plus reserpine-treated	2.8 ± 1.3	(4)	15

Experimental groups were significantly different from control ($p < 0.01$). Values shown are Mean ± Standard Error (N).

When the above test is repeated, the following specific activity (% of control) for smooth muscle cell DNA after vascular injury and antiserotonin treatment are found:

		Specific Activity	Standard Error (%)	Number of Animals	
20	Untreated	100	15	7	20
25	Vehicle treated	92	21	5	25
30	Reserpine treated	68	12	4	30
35	Methiothepin treated*	23	4	10	35
	Methiothepin and Reserpine treated*	10	3	8	

*Statistically different from control ($p < 0.01$).

When the above procedure is carried out using various amounts of methiothepin, the following dose dependent specific activities are found:

		Specific Activity	Standard Error (%)	Number of Animals	
40	Vehicle	100	16	7	40
45	Methiothepin 0.3 mg/kg	51	5	5	45
	Methiothepin 1.0 mg/kg	24	4	6	
50	Methiothepin 3.0 mg/kg	23	7	6	50
	Methiothepin 10.0 mg/kg	20	7	6	

Example 5

This example demonstrates the reduction in the size of vascular lesions obtained with the serotonin receptor, blocker, pizotyline.

Male Sprague-Dawley rats weighing 300-360 grams are individually ear tagged, housed and allowed to acclimatize for two weeks prior to the start of the test. A constant formula rodent lab chow from Ralton Purina and water are available to the animals ad libitum.

For two days prior to de-endothelialization and for 14 days after, pizotyline at a dose of 25 milligrams per kilogram and placebo are administered by gavage in physiological saline to nine drug animals and 19 control animals. All animals are dosed between 8:00 and 10:00 A.M. daily. On the day of surgical de-endothelialization, the drug is administered intravenously (femoral vein) at 1/10 the oral dose in order to achieve optimal blood compound levels. There is a minimum period of five minutes between dose and

actual insertion of the catheter. The animals are weighed daily at this time of dosing and behaviour for each

55

60

65

animal is recorded three to four hours after dosing. The animals are examined individually for approximately one minute for overt signs and symptoms and then returned to their cages.

On the day of de-endothelialization, the animals are anesthetized by ether inhalation and catheterization is carried out by the following procedure. The left femoral artery is exposed and lidocaine-HCl is applied locally to desensitize and dilate the blood vessel. The catheter balloon tip is advanced cephalic to the aortic arch region as determined through external catheter demarcations and inflated to a pre-established maximum diameter with approximately 900 mm Hg air pressure. The inflated catheter is drawn caudally to the bifurcation of the iliac arteries and deflated. This sequence is repeated three times as the catheter is twisted to assure symmetrical de-endothelialization of the vessel. The deflated balloon catheter is then removed and followed by ligation of the artery and area closure.

On the fourteenth day following the de-endothelialization, whole body (beating heart) perfusion fixations are performed on the anesthetized and heparinized animals utilizing approximately 200 milliliters of a 3% buffered glutaraldehyde in 0.15 moles of sodium cacodylate at a pH of 7.4 under 90-100 mm hydrostatic pressure at 37°C. The entry site for the catheter is a left ventricular puncture and insertion is into the aortic arch. Efflux was collected via vacuum suction from the right atrium. The aorta is then removed and cut into 10 equal segments (Nos. 1-6 thoracic, Nos. 7-10 abdominal). The segments are subjected to an additional two-hour period in 3% buffered glutaraldehyde, buffer washing, and postfixation with 1% osmium tetroxide for 18 hours at 4°C.. Following the postfixation, the segments are infiltrated with Spurr's resin and cured at 70°C. Segments 2, 3, 8 and 9 are longitudinally sectioned at 0.5 µm thickness. A two-step polychromatic stain utilizing Stevenel's blue (2.0% KMnO₄, 1.3% methylene blue) and basic fuchsin (1.0%) is used to render histological differentiation to nuclear, cytoplasmic and extracellular (including neointimal) components. Lesions from the vessel segments are recorded as a sectional area in µm² utilizing a Zeiss standard microscope and the Videoplan computerized image analyzer; and the values are normalized to 1,000 µm in length. Lesions exhibiting re-endothelialization are included in the analysis. Values from thoracic and abdominal segments were not pooled, as there is significant evidence to indicate a difference in rate of endothelial cell regrowth that affects lesion dimensions. The lesion-section area values are set out below in Table V:

Table V - Mean Lesion Area in µm² From Control and Treated Animals

		Thoracic	Abdominal	
30	Control	50,283.1	60,310.3	30
35	Pizotyline	11,834.8	27,135.4	35

The animals treated with pizotyline consistently demonstrated reduced lesion formation in the thoracic segments with a mean reduction of 77% as compared to control lesion areas. Lesion formation in the abdominal segments is reduced by 55% in a similarly consistent manner.

40 Similar results are obtained with the following agents at the dose indicated:

	Agent	Dose (mg/kg)	
45	Metergoline	3.5	45
	Cyproheptadine	25.0	
	Methysergide	46.0	
50	Spiroperidol	4.6	50
	Ketanserin	8.0	
	Mianserin	50.0	
55	Pipamperone	20.0	55

Examples 6 and 7**Tablets and Capsules Suitable for Oral Administration**

Tablets and capsules containing the ingredients indicated below may be prepared by conventional techniques and are useful in preventing smooth muscle cell proliferation at a dose of one tablet or capsule a 5 day.

5

	Ingredient	Tablet	Weight (mg.) Capsule	
10	Methiothepin	10	10	10
	Reserpine	0.5	0.5	
15	Tragacanth	10	-	15
	Lactose	197.5	-	
	Corn Starch	25	-	
20	Talcum	15	-	20
	Magnesium Stearate	2.5	-	

CLAIMS

- 25 1. A pharmaceutical composition for use in inhibiting sooth cell proliferation comprising a mixture of at least two drugs wherein each drug is from a different group of drugs selected from (i) tryptophan hydroxylase inhibitors, (ii) peripheral decarboxylase inhibitors, (iii) serotonin uptake blockers, (iv) serotonin storage blockers and (v) serotonin receptor blockers.
- 30 2. A composition according to claim 1 wherein the mixture contains at least one serotonin receptor blocker selected from pizotyline, methiothepin, metergoline, cyproheptadine, methysergide, spiroperidol and mianserin.
- 35 3. A composition according to claim 1 or 2 which comprises a serotonin receptor blocker and at least one tryptophan hydroxylase inhibitor, peripheral decarboxylase inhibitor, serotonin uptake blocker or serotonin storage blocker.
- 40 4. A composition according to claim 1, 2 or 3 which comprises reserpine as an active ingredient, in combination with a serotonin receptor blocker.
5. A composition according to claim 4 which comprises methiothepin and reserpine.
6. A composition according to claim 4 which comprises cyproheptadine and reserpine.
7. A composition according to any one of the preceding claims which also includes a platelet-inhibitor drug.
8. A composition according to claim 1 substantially as described with reference to Example 6 or 7.

Printed for Her Majesty's Stationery Office, by Croydon Printing Company Limited, Croydon, Surrey, 1983.
Published by The Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.